Mirati Therapeutics (MRTX) PT Lowered to $155 at Oppenheimer, Following Clinical Business Update
Tweet Send to a Friend
Oppenheimer analyst Jay Olson lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $155.00 (from $175.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
